Elizabeth Garriga, NP
Psychiatric/Mental Health · Gulfport, MSNPI 1962165852
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 192 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,491 and has fallen 98.1% since, to $28 in 2025.
Across 192 payments — averaging $20.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$734
- AbbVie$673
- Johnson & Johnson$598
- Supernus Pharmaceuticals, Inc.$386
- Neurocrine Biosciences, Inc.$375
- Indivior Inc.$291
- plus $903 from 7 others
What the payments were for
- Food & beverage$3,959100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 28 | $734 |
| AbbVie | 42 | $673 |
| Johnson & Johnson | 38 | $598 |
| Supernus Pharmaceuticals, Inc. | 1 | $386 |
| Neurocrine Biosciences, Inc. | 18 | $375 |
| Indivior Inc. | 18 | $291 |
| Alkermes, Inc. | 14 | $271 |
| Teva Pharmaceuticals USA, Inc. | 11 | $227 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $184 |
| Lundbeck LLC | 8 | $136 |
| Otsuka America Pharmaceutical, Inc. | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,959 in reported general payments places this provider in the 85th percentile of 486 psychiatric/mental health providers in Mississippi.
See all psychiatric/mental health providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 23 | $190,529 |
| Invega SustennaPaliperidone Palmitate | 42 | $140,784 |
| Austedo XrDeutetrabenazine | 17 | $109,644 |
| VraylarCariprazine Hcl | 66 | $98,673 |
| Abilify MaintenaAripiprazole | 24 | $62,094 |
| Risperdal ConstaRisperidone Microspheres | 11 | $25,423 |
| TrintellixVortioxetine Hydrobromide | 37 | $19,292 |
| Lurasidone Hcl | 28 | $2,953 |
| Divalproex Sodium ErDivalproex Sodium | 60 | $2,092 |
| Haloperidol Decanoate | 24 | $1,944 |
| Olanzapine | 88 | $1,803 |
| Aripiprazole | 61 | $1,514 |
| Clozapine | 21 | $1,422 |
| Haloperidol | 33 | $1,251 |
| Ziprasidone Hcl | 19 | $876 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $375 | $190,52923 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $598 | $166,20753 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $227 | $109,64417 claims |
| AbbVieVraylar | $673 | $98,67366 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $54 | $62,09424 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $17 | $19,29237 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 486 psychiatric/mental health providers in Mississippi.
Other psychiatric/mental health in Gulfport
- Desiree NormanGulfport$10K
- Tangular BarnesGulfport$9K
- Anita HallGulfport$8K
- Belinda HoldenGulfport$7K
- Chantal SullivanGulfport$7K
- Anne TuckerGulfport$5K
- Kari WilliamsGulfport$4K
- Jo DrennanGulfport$4K
- Ashley KarelVicksburg$129K
- Amanda HamCorinth$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.